AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04551586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Powder-in-capsule
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.
Study NCT02013908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture plus standard ED management
Study NCT02013908 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ED management alone
Study NCT04162158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic NK cells therapy
Description: PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
Study NCT03190083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital breast tomosynthesis (DBT)
Description: The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
Study NCT00688961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: generic aspirin
Study NCT00688961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 acid ethyl esters
Description: 4, 1 g capsules q.d.
Study NCT03869242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A
Description: newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
Study NCT03869242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-200A
Description: newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
Study NCT03155191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI-1501
Description: Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501.
Study NCT05752578 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological testing
Description: During the session the patient will be administered the Memory for Intentions Screening Test (MIST; Raskin et al., 2010) with the purpose of investigating prospective memory ability. Then during the same meeting the following tests will be offered to the patient: Montreal Cognitive Assessment (MOCA; Nasreddine. Translation Pirani et al 2006) investigating global cognitive performance; - Interpersonal Reactivity Index (IRI; Davis, 1980;1983- Italian version edited by Bonino et al, 1998) with the purpose of assessing cognitive and affective empathy (Hot cognition); Modified Five Point Test (Ruffi et al 1987) aimed at assessing figurative fluency (Cold cognition).
Study NCT01765660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-mesenchymal stem cells
Description: Other second line drugs are taken.
Study NCT03312400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
Study NCT03280043 — intervention group
Intervention type: PROCEDURE
Intervention: Hematoma
Description: Hematoma requiring return to operating room.
Study NCT03370289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLB-750 Vaccine (Qinghai RG strain)
Description: BLB-750 Injection
Study NCT05570201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention was applied to the women in the control group, only the questionnaires (pre-test, post-test) were filled out. Filling the questionnaires lasted 10-15 minutes on average in all groups
Study NCT04214184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased sleep duration
Description: Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
Study NCT02734420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PapacarieMBlue and PDT
Description: Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
Study NCT02734420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toluidine Blue O and PDT
Description: Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
Study NCT02734420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Study NCT00590460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H
Description: Given intravenous on days -8, -7, and -6
Study NCT00590460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg
Study NCT00590460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2
Study NCT00590460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Stem cells are infused on day 0
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match manipulated oxycodone IR ADF.
Description: Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
Study NCT01657682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate
Description: Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
Study NCT04837950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic traction-suture
Description: Measurement of pleural cavity volume before pulling the diaphragmatic traction-suture Measurement of pleural cavity volume after pulling the diaphragmatic traction-suture
Study NCT00847093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX4
Description: One inch every six hours
Study NCT00847093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMX4 Placebo
Description: One inch every six hours
Study NCT03487874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional interscalene block
Description: Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
Study NCT03487874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene block with C8 root block
Description: Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
Study NCT03487874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Study NCT03487874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
Study NCT04239287 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function + exercise tests
Description: Lung function + exercise tests
Study NCT04887961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD and Trabectedin rechallenge
Description: Platinum partially sensitive patients i.e. patients who recur with a platinum free interval between 6 and 12 months, who have previously received pegylated liposomal doxorubicin and are suitable for rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) and relapsed ovarian cancer fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments
Study NCT01373047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA 2nd generation designer T cells
Description: Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
Study NCT02284464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal
Description: Withdrawal of steroids
Study NCT02284464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone continuation
Description: Continuation of steroids
Study NCT01894958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study NCT01894958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution
Study NCT03291600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Psychiatric Care
Description: Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
Study NCT01882894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom PFO
Description: PFO made out of thermoplastic material molded to the patient's foot
Study NCT01882894 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faux orthosis
Description: Foam cut out
Study NCT03906487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM
Description: This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~* the last to characterize the SDM by defining 5 personal memories
Study NCT03906487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment measures MINI and definition of 5 SDM
Description: This group will have two visits:~* the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~* the last to characterize the SDM by and defining 5 personal memories
Study NCT02916472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CyberCycling
Description: All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
Study NCT02916472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
Study NCT02916472 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Bands
Description: Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins.
Study NCT03122964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AssureMDx
Description: combined panel of methylation and mutation markers for the detection of bladder cancer
Study NCT01340833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) \[14C\]GSK2118436, starting 1.75 hours after the oral dose
Study NCT02742909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBNP
Description: rhBNP was administered as a continuous infusion for 24 hours before or after placebo
Study NCT02742909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline as a placebo was administered as a continuous infusion for 24 hours
Study NCT02687919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Paleo diet
Description: Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
Study NCT04400708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of 0.5% ropivacaine 15ml is given.
Study NCT04400708 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: After the end of the surgery, at the arrival of PACU, the patient's leg is prepared and draped in a sterile manner. Assisted by the high-frequency linear ultrasound transducer, we target the mid-thigh level and the 22-gauge/8cm needle is introduced in plain through the sartorius muscle. the correct position for the tip of the needle in the adductor canal is checked and a bolus injection of normal saline15ml is given.
Study NCT03068286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in Diabetes
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
Study NCT03580304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Industrial work
Description: Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
Study NCT03068286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in COPD
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
Study NCT03068286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space in Chronic Pain
Description: The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain.
Study NCT02999997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ronnie Gardiner Method (RGM)
Description: RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
Study NCT01623427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of vacuum
Description: The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
Study NCT04734041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Anti-inflammatory (Mediterranean-style) diet
Description: Prescription of an anti-inflammatory diet, which encourages increasing whole fruits, vegetables, and grains, as well as balancing macronutrients (proteins, carbohydrates, and fat) for every meal.
Study NCT04734041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and psychosocial support
Description: Capture a complete and detailed medical history and background. Discuss familial and social support, provide psychosocial support, assess the patient's current self-management strategies for self-care, and assess the patient's current self-management strategies for mental health. Recommendations will be made in accordance with the needs of the participant.
Study NCT00329303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (Cimzia®)
Description: * Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use~* Dose and Administration details :~  2 x 1 mL Certolizumab Pegol at Week 0, followed by~* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10
Study NCT01257165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Zopiclone pill 5 or 10 mg, given orally as a single dose.
Study NCT03259542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 MG
Description: mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
Study NCT03259542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 MG
Description: itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing